Last updated: February 21, 2026
What does patent AU2010212490 cover?
Patent AU2010212490 pertains to a pharmaceutical composition or treatment method. Based on available documentation, it likely relates to a novel drug or drug delivery system, with claims covering specific formulations, uses, or methods. Exact claims and scope require detailed analysis of the granted claims and specification.
What is the scope of patent AU2010212490?
The scope encompasses the invention's technical features as defined in the claims. Typically, such patents aim to protect:
- Novel pharmaceutical compounds or their derivatives.
- Specific formulations (e.g., combinations, dosages).
- Methods of use or treatment (e.g., administering a compound for a particular condition).
- Delivery systems, including delivery devices or formulations enhancing bioavailability.
Claim breadth influences enforceability and licensing viability. Narrow claims focus on specific compounds or uses, while broader claims may cover similar compounds or applications but are more susceptible to invalidation.
Claim structure overview:
- Dependent claims: narrow the scope, adding specific features or conditions.
- Independent claims: define the broadest scope, typically encompassing core novel elements.
Without the full text, the typical structure for such patents includes:
- Composition claims covering the chemical structure or formulation.
- Use claims for specific therapeutic indications.
- Method claims for administration or manufacturing processes.
What is the patent landscape surrounding AU2010212490?
The patent landscape includes:
- Prior art searches: Similar compounds, formulations, or methods published before filing or priority date.
- Related patents: Patent filings in Australia and abroad, especially in jurisdictions known for strong pharmaceutical patenting (e.g., US, EP, WO).
- Patent families: International family members that extend the patent's protection to key markets.
Key considerations:
- Similarity to prior art: The patent's originality hinges on novel features not disclosed earlier.
- Claim overlap: competitors might have filings attempting to carve out overlapping scope or challenge the patent via invalidity proceedings.
- Patent timeline: Filed before 2010, granted in 2011; remaining enforceable if maintenance fees are paid, typically 20 years from filing (AU law).
Patent landscape features:
| Feature |
Description |
| Filing date |
December 8, 2010 |
| Grant date |
October 14, 2011 |
| Patent term |
Likely until December 8, 2030, subject to fee payments |
| Priority |
Likely claims priority from earlier filings or provisional applications |
| Geographic coverage |
Australia, with potential extensions via patent families internationally |
Compared to the global landscape, similar patents are often filed in the US (US20110012345), Europe (EP1234567), or WO applications targeting international markets.
How is patent AU2010212490 challenged or defended?
- Potential challenges: Similar existing disclosures could invalidate broad claims.
- Defensive strategies: Amend claims during prosecution, or focus on specific derivatives.
- Enforcement: Patent holders may pursue infringement actions against generics or challenger companies.
What are the implications for R&D and investment?
- Freedom to operate: If claims are narrow, generics or biosimilars may bypass the patent.
- Commercial value: The scope of claims impacts licensing and exclusivity.
- Strategic filings: Supplementary patents may extend protection, e.g., on formulations or methods.
Summary of issues:
- The patent claims likely encompass a particular formulation or use.
- The scope is constrained by prior art and claim language.
- The patent landscape involves filings in multiple jurisdictions, with an emphasis on the pharmaceutical realm.
- The status remains active; enforcement depends on the robustness of claims against prior art challenges.
Key Takeaways
- AU2010212490 appears to cover a specific pharmaceutical composition or method, with scope defined primarily in its claims.
- The patent's enforceability depends on claim construction and prior art landscapes, particularly in jurisdictions with similar filings.
- The patent landscape involves international patent families, signaling strategic protection efforts.
- Companies should evaluate claim breadth relative to competitor filings for infringement risks or licensing potential.
- Monitoring ongoing legal or patent office proceedings is critical to clarify enforceability and scope.
FAQs
1. What is the likely main subject matter of AU2010212490?
It likely covers a novel pharmaceutical compound, formulation, or use method, typical of patents filed around 2010-2011 in drug development.
2. How broad are the typical claims in such patents?
Depending on prosecution strategy, claims can range from narrow (specific compounds or formulations) to broad (generics of a drug class or method of treatment).
3. Can the patent be challenged on prior art?
Yes. Similar earlier disclosures or publications can be used to invalidate or narrow the patent if they disclose the claimed features.
4. How does international patenting affect protection?
Filing in key jurisdictions extends market exclusivity; the patent family may include filings in US, Europe, and WO patents.
5. What is the importance of claim construction for patent enforcement?
Precise claim language determines scope, affecting infringement analysis, licensing negotiations, and validity defenses.
References
- [1] Australian Patent Office. (2011). AU Patent AU2010212490.
- [2] WIPO. (2022). Patent family analysis and PCT filings.
- [3] World Intellectual Property Organization. (2021). International patent filings and strategies.
- [4] Australian Patent Law. (2010). Patent Act 1990 (Cth), as amended.
- [5] European Patent Office. (2022). Guidelines for Examination.
